IL6 and COVID-19: Blocking IL-6 signaling as a therapeutic intervention has been extensively studied in many diseases (161, 162), and COVID-19 randomized controlled clinical trials with biologics targeting the IL-6 receptor, including the Tocilizumab antibody, have shown evidence of clinical benefit (163–166).